<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine whether patients with cerebral <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> with subcortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (CADASIL) had evidence of increased <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels compared with non-CADASIL patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We compared fasting plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels and levels 6 hours after oral loading with methionine, 100 mg/kg, in non-CADASIL patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> and in patients with CADASIL </plain></SENT>
<SENT sid="2" pm="."><plain>Prechallenge, postchallenge, and change in <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels between the 2 groups were compared with use of the Wilcoxon rank sum test </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: CADASIL and non-CADASIL groups were similar in age (mean, 48.8 vs. 46.5 years, respectively; 2-tailed t test, P=.56) and sex (men, 86% vs 59%; Fisher exact test, P=.12) </plain></SENT>
<SENT sid="4" pm="."><plain>The 59 patients in the CADASIL group had higher median plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels compared with the 14 patients in the non-CADASIL group, both in the fasting state (12.0 vs 9.0 micromol/L; P=.03) and after methionine challenge (51.0 vs 34.0 micromol/L; P=.007) </plain></SENT>
<SENT sid="5" pm="."><plain>Median difference between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels before and after methionine challenge was greater in the CADASIL group than in the non-CADASIL group (34.5 vs. 24.0 micromol/ L; P = .02) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Our findings raise the possibility that increased <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels or <z:hpo ids='HP_0010919'>abnormalities of homocysteine metabolism</z:hpo> may have a role in the pathogenesis of CADASIL </plain></SENT>
</text></document>